Ryan Connelly - LeMaitre Vascular Vice President - Research & Development
| LMAT Stock | USD 99.06 0.83 0.84% |
President
Mr. Ryan H. Connelly Vice President Research Development of LeMaitre Vascular Inc. Mr. Connelly joined us in 2002 and has held the positions of RD Engineer, Senior RD Engineer, and CoGeneral Manager of our Phoenix facility during that time. In 2006, Mr. Connelly was promoted to Director, Research and Development. From 2001 to 2002, Mr. Connelly worked as a research and development engineer at Panduit Corporationrationration, a network and electrical solutions provider since 2011.
| Age | 48 |
| Tenure | 14 years |
| Address | 63 Second Avenue, Burlington, MA, United States, 01803 |
| Phone | 781 221 2266 |
| Web | https://www.lemaitre.com |
LeMaitre Vascular Management Efficiency
The company has return on total asset (ROA) of 0.0872 % which means that it generated a profit of $0.0872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1334 %, meaning that it created $0.1334 on every $100 dollars invested by stockholders. LeMaitre Vascular's management efficiency ratios could be used to measure how well LeMaitre Vascular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.1 in 2025, whereas Return On Tangible Assets are likely to drop 0.06 in 2025. At this time, LeMaitre Vascular's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 418.7 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 1.8 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Virginia Sanzone | ICU Medical | 50 | |
| Brian Andrews | The Cooper Companies, | 46 | |
| Jan Verstreken | Hologic | 57 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Anila Lingamneni | Haemonetics | 57 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| James Darecca | Haemonetics | 50 | |
| Daniel Woolson | ICU Medical | 48 | |
| Randal Golden | The Cooper Companies, | 57 | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Jennifer Schneiders | Hologic | 56 | |
| Michelle Basil | Haemonetics | 52 | |
| James McAvinn | Milestone Scientific | N/A | |
| Stewart Strong | Haemonetics | 58 | |
| Roy Galvin | Haemonetics | 54 | |
| Holly Sheffield | The Cooper Companies, | 54 | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
| William Burke | Haemonetics | 52 | |
| Daniel McBride | The Cooper Companies, | 56 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0872 |
LeMaitre Vascular Leadership Team
Elected by the shareholders, the LeMaitre Vascular's board of directors comprises two types of representatives: LeMaitre Vascular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LeMaitre. The board's role is to monitor LeMaitre Vascular's management team and ensure that shareholders' interests are well served. LeMaitre Vascular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LeMaitre Vascular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Roberts, President Director | ||
| Jonathan Ngau, Senior Technology | ||
| George LeMaitre, Chairman and CEO | ||
| Trent Kamke, Sr. VP of Operations | ||
| Kimberly Cieslak, Vice President - Marketing | ||
| Ryan Connelly, Vice President - Research & Development | ||
| Laurie Churchill, Senior Vice President General Counsel | ||
| Maik Helmers, Senior Europe | ||
| Joseph Pellegrino, CFO, Principal Accounting Officer and Secretary | ||
| Stephane Maier, Vice President EMEA Operations | ||
| Daniel Mumford, Director Resources | ||
| David Hissong, General Counsel | ||
| Andrew Hodgkinson, Senior Vice President - Clinical, Regulatory and Quality Affairs |
LeMaitre Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LeMaitre Vascular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 2.12 B | ||||
| Shares Outstanding | 22.48 M | ||||
| Shares Owned By Insiders | 8.87 % | ||||
| Shares Owned By Institutions | 93.68 % | ||||
| Number Of Shares Shorted | 1.21 M | ||||
| Price To Earning | 38.99 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for LeMaitre Stock Analysis
When running LeMaitre Vascular's price analysis, check to measure LeMaitre Vascular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LeMaitre Vascular is operating at the current time. Most of LeMaitre Vascular's value examination focuses on studying past and present price action to predict the probability of LeMaitre Vascular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LeMaitre Vascular's price. Additionally, you may evaluate how the addition of LeMaitre Vascular to your portfolios can decrease your overall portfolio volatility.